Skip to main content

Market Overview

Arena Pharmaceuticals Q4 Earnings Preview

Share:

Don't be caught off-guard: Arena Pharmaceuticals (NASDAQ: ARNA) releases its next round of earnings Tuesday.

Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters guide for today's Q4 earnings announcement after the bell.

Earnings and Revenue

Wall Street analysts see Arena Pharmaceuticals reporting a quarterly loss of 59 cents per share on sales of $7.57 million.

In the same quarter last year, Arena Pharmaceuticals announced EPS of 25 cents on revenue of $85.37 million. Analysts estimate would represent a 336 percent increase in the company's earnings. Revenue would be down 91.13 percent from the same quarter last year.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:

 

Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.67 -0.74 -0.07 -0.08
EPS Actual -0.55 -0.77 -0.09 0.25

 

Stock Performance

Over the last 52-week period, shares are up 171.62 percent. Given that these returns are generally positive, long-term shareholders can be satisfied going into this earnings release. Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. The popular rating by analysts on Arena Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

 

Related Articles (ARNA)

View Comments and Join the Discussion!

Posted-In: Earnings News Previews Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com